Results 131 to 140 of about 26,674 (238)

Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundWe examined the cardiovascular risk of abatacept compared with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus (DM). Methods and ResultsWe conducted a cohort study of patients with
Eun Ha Kang, Yinzhu Jin, Gregory Brill, Jennifer Lewey, Elisabetta Patorno, Rishi J. Desai, Seoyoung C. Kim   +6 more
doaj   +1 more source

Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study [PDF]

, 2016
Objectives To explore whether changes in a composite (power Doppler/greyscale ultrasound (PDUS)) synovitis score, developed by the OMERACT-EULAR-Ultrasound Task Force, predict disease activity outcomes in rheumatoid arthritis (RA).
Balint, P, Berner Hammer, H, Boers, M, D'Agostino, M-A, Filippou, G, Gaillez, C, Iagnocco, A, Le Bars, M, Möller, I, Naredo, E, Vittecoq, O, Wakefield, RJ, Østergaard, M   +12 more
core   +9 more sources

Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients. [PDF]

, 2015
BACKGROUND: CD28(neg) T cells, which display functional characteristic of oligoclonally expanded cytotoxic memory T lymphocytes, are believed to be pathologically relevant in rheumatoid arthritis manifestation.
Airò, P, Bertoli, D, Chiarini, M, Imberti, L, Scarsi, M, Tincani, A, Zanotti, C   +6 more
core   +1 more source

Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting. [PDF]

, 2014
Rheumatoid arthritis (RA) is an inflammatory autoimmune condition typified by systemic inflammation targeted toward synovial joints. Inhibition of proinflammatory networks by disease-modifying antirheumatic drugs, eg, methotrexate and biologic therapies,
Ahmed, S, Harrison, A, Magan, T, Sofat, N, Vargas, M   +4 more
core   +2 more sources

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis

Therapeutics and Clinical Risk Management, 2014
Chadi Rakieh, Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UKAbstract: Biologic therapies in rheumatoid arthritis are now part of standard ...
Rakieh C, Conaghan PG
doaj  

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study

RMD Open, 2019
Objectives To complete reporting of outcomes after total withdrawal of all rheumatoid arthritis (RA) therapy and re-treatment after flare in Assessing Very Early Rheumatoid arthritis Treatment study (NCT01142726).Methods Patients with early RA were ...
Daniel E Furst, Paul Emery, Gerd R Burmester, Vivian P Bykerk, Bernard G Combe, Michael A Maldonado, Tom WJ Huizinga   +6 more
doaj   +1 more source

Eosinophilic fasciitis (Shulman's disease): review and comparative evaluation of seven patients. [PDF]

, 2019
OBJECTIVES: Eosinophilic fasciitis (EF) was described in 1974 by Shulman as a rare fibrosing connective tissue disease of unknown etiology. An undetermined trigger is thought to lead to the degranulation of eosinophils that interact with fibroblasts and
Cimbron, M, Farinha, F, Mendonça, T, Urzal, J   +3 more
core   +1 more source

Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner

Arthritis Research & Therapy, 2018
Background The anti-inflammatory effect of abatacept is most pronounced in patients with high-titer autoantibodies (including anticitrullinated protein antibodies [ACPA] and rheumatoid factor [RF]).
Aline Bozec, Yubin Luo, Cecilia Engdahl, Camille Figueiredo, Holger Bang, Georg Schett   +5 more
doaj   +1 more source

Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus

Clinical and Developmental Immunology, 2013
Introduction. This study aimed to investigate the efficacy of abatacept for arthritis in patients with rhupus, an overlap syndrome between rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods. Patients who fulfilled both the 2010 ACR/
Kei Ikeda, Yoshie Sanayama, Sohei Makita, Junichi Hosokawa, Mieko Yamagata, Daiki Nakagomi, Katsuhiko Takabayashi, Hiroshi Nakajima   +7 more
doaj   +1 more source

Costo efectividad de Abatacept en comparación con otras terapias biológicas para el tratamiento de la artritis reumatoide moderada a severamente activa en pacientes que han fallado al tratamiento con metotrexato en EsSalud para el año 2010

Acta Médica Peruana
Objetivo: Estimar la costo efectividad de Abatacept combinado con Metotrexato (MTX) en comparación a otras DARMEs biológicas, en combinación con MTX, en pacientes con AR moderada a severamente activa.
Felipe Becerra Rojas, César Benites Chacaltana, Eleonora Aiello, Carolina Zingoni, Gert Bergman, Pieter Drost, César Sanabria Montañez   +6 more
doaj